Compare Recursion Pharmaceuticals Inc (RXRX) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vistra Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Vistra Corp trades at $162.2 (market cap $53.27B). The key difference: Vistra Corp is far larger — about 34.8× Recursion Pharmaceuticals Inc's market cap, and Vistra Corp pays a 0.58% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | VST | |
|---|---|---|
Market Cap | $1.53B | $53.27B |
Sector | Health | Technology |
52-Week High | $6.79 | $217.92 |
52-Week Low | $2.84 | $134.71 |
Enterprise Value | $946.50M | $75.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Vistra Corp (VST) trades at $157.99, up 1.64% with strong institutional support and bullish technical signals. The stock shows robust fundamentals with 74.92% ROE and 11.52% net margin, though recent earnings were mixed with Q1 2026 beating expectations but Q3 and Q4 2025 missing. Analyst consensus remains overwhelmingly positive with 91% buy ratings and a $253 price target, representing 60% upside potential. Recent news highlights Vistra's positioning in the AI power infrastructure boom and long-term power purchase agreements with major tech companies.
Vistra presents significant growth potential driven by AI infrastructure demand and nuclear energy expansion, but faces risks from power price volatility and high debt levels. The company's diversified utility operations and strategic PPAs provide revenue stability, while technical indicators suggest continued upward momentum with key resistance at $159-$162. Investors should weigh the strong analyst support against execution risks in capital-intensive energy projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
